Non-executive appointment

Ardana PLC 17 June 2005 ARDANA APPOINTS NEW NON-EXECUTIVE TO THE BOARD Edinburgh, UK, 17 June 2005; Ardana, the emerging pharmaceutical company focused on improving human reproductive health, today announces that Carol Ferguson has been appointed as a non-executive director and as Chair of the audit committee. From 1990-1996 Mrs Ferguson was Finance Director of Timney Fowler Ltd, a textile design company. Prior to this she was a financial journalist and columnist for The Times drawing on her 14 years experience in investment, fund management, research and sales. Between 1977-1987, she headed up the oil department at stockbrokers Wood Mackenzie & Co in Edinburgh and was ranked No 1 oil analyst by Extel for six successive years. Since leaving Timney Fowler, Mrs Ferguson has been involved with several public, private and voluntary organisations in a non-executive or advisory capacity, primarily chairing audit committees. In 2002, she was elected a member of the executive committee of the Association of Investment Trust Companies and was recently appointed a Deputy Chairman. Current non-executive appointments include Monks IT, Gartmore Smaller Companies IT, Merrill Lynch Greater Europe IT and Vernalis plc. Maureen Lindsay, CEO of Ardana, said: 'Carol brings considerable financial expertise to our Board and we are delighted that she is joining us. She has an impressive background and her current directorships demonstrate how highly she is valued in an advisory capacity. Her contributions will be invaluable as we take our product pipeline closer to commercialisation.' For more information contact: Ardana Financial Dynamics Maureen Lindsay (corporate/financial media relations) Tel: + 44 (0) 131 226 8550 Julia Phillips/Davina Langdale Tel: +44 (0)20 7831 3113 NB Public Relations (trade/technical media relations) Nicki Brimicombe Tel: + 44 (0)1883 732353 About Ardana Ardana plc is a pharmaceutical company focused on the discovery, development and marketing of innovative products to improve human reproductive health, a $23.8 billion market. Since its foundation, Ardana has maintained a broad and balanced portfolio to manage risk and actively pursues product and technology in-licensing and outlicensing to maintain a robust pipeline. Ardana's four lead products are summarised below: • StriantTM SR, a testosterone replacement therapy that has already been launched by Ardana through its own sales force in the UK as a treatment for men with hypogonadism and for which Ardana has marketing rights in Europe; • Teverelix LA, in development for three initial indications (prostate cancer, BPH and endometriosis); • Testo Bi-gel, a trans dermal testosterone delivery system in development for the treatment of male hypogonadism, shortly to enter Phase II trials; • Invicorp, an injectable combination drug treatment for erectile dysfunction, for which Ardana has marketing and manufacturing rights in Europe. In addition, Ardana has a strong portfolio of follow-on products in development. Ardana completed its IPO on the London Stock Exchange in March 2005 raising £21 million. For further information please see www.ardana.co.uk This information is provided by RNS The company news service from the London Stock Exchange